CytomX Shares Surge on Strong Phase 1 Data for Varsetatug Masetecan in Late-Line Colorectal Cancer

Shares of CytomX Therapeutics surged after strong Phase 1 trial data for Varsetatug Masetecan showed tumor shrinkage in late-stage colorectal cancer patients with mostly mild side effects.